7.04
-0.32(-4.35%)
Currency In USD
| Previous Close | 7.36 |
| Open | 7.31 |
| Day High | 7.34 |
| Day Low | 6.93 |
| 52-Week High | 8.05 |
| 52-Week Low | 3.21 |
| Volume | 5M |
| Average Volume | 4.09M |
| Market Cap | 1.69B |
| PE | -30.61 |
| EPS | -0.23 |
| Moving Average 50 Days | 5.9 |
| Moving Average 200 Days | 5.1 |
| Change | -0.32 |
If you invested $1000 in Ardelyx, Inc. (ARDX) 10 years ago, it would be worth $2,676.81 as of January 14, 2026 at a share price of $7.04. Whereas If you bought $1000 worth of Ardelyx, Inc. (ARDX) shares 5 years ago, it would be worth $4,069.36 as of January 14, 2026 at a share price of $7.04.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
GlobeNewswire Inc.
Jan 08, 2026 1:30 PM GMT
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241 IBSRELA expected to achieve $410-430 million in r
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
GlobeNewswire Inc.
Nov 07, 2025 9:05 PM GMT
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
GlobeNewswire Inc.
Nov 05, 2025 1:00 PM GMT
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs